

Agency for International Development
Washington, D.C. 20523

938-0801
PDFCU104

AUG 27 1991

The Foundation for the Peoples
of the South Pacific (FPSP)
3550 Afton Road
San Diego, CA 92123

Attn: Rev. Stanley W. Hosie
Subject: Grant No. PDC-0500-G-00-1075-00

Dear Rev. Hosie:

Pursuant to the authority contained in the Foreign Assistance Act of 1961, as amended, the Agency for International Development (hereinafter referred to as "A.I.D." or "Grantor") hereby grants to The Foundation for the Peoples of the South Pacific (FPSP), hereinafter referred to as "FPSP" or "Grantee") the sum of \$500,000. This funding is provided as support for FPSP's proposal dated July 15, 1991 entitled "Child Survival VII program in the Solomon Islands" which is hereby incorporated by reference into this Grant, and which is more fully described in Attachment 2 to this Grant, entitled "Program Description."

This Grant is effective and obligation is made as of the date of this letter and shall apply to commitments made by the Grantee in furtherance of project objectives during the period from September 15, 1991 to September 14, 1994. Funds disbursed by A.I.D., but uncommitted by the Grantee at the expiration of this period, shall be refunded to A.I.D.

This Grant is made to FPSP on the condition that the funds will be administered in accordance with the terms and conditions as set forth in this cover letter, Attachment 1, entitled "The Schedule," Attachment 2, entitled "Program Description," Attachment 3, entitled "Standard Provisions," Attachment 4, (not applicable), and Attachment 5, entitled "Special Provision 40.1. which have been agreed to by your organization constitute the complete Grant agreement.

The total estimated amount of A.I.D. support is \$500,000, of which the entire amount is hereby obligated. A.I.D. shall not be liable for reimbursing the Grantee for any costs in excess of the obligated amount.

Please sign the original and all copies of this letter to acknowledge your receipt of the Grant, retain one set for your files, and return the original and remaining copies to the undersigned.

Sincerely,

Edward H. Thomas

Edward H. Thomas
Grants Officer
Washington Division
Office of Procurement

Attachments:

1. The Schedule
2. Program Description
3. Standard Provisions
4. Not applicable
5. Special Provision 40.1

ACKNOWLEDGED:

FPSP

BY: *Stan G. W. Dossie*

Title: Executive Director

Date: September 10, 1991

FISCAL DATA

PIO/T(s)	: 1385018
Appropriation	: 72-1111021.7
Allotment	: 147-38-099-00-76-11
Budget Plan Code	: EDCA-91-13810-KG11
Obligated Amount(s)	: \$500,000
Total Obligation(s)	: \$500,000
Total Grant Amount	: \$500,000
Unobligated	: 0

DUNS NO.	:	073268229
TIN	:	136183605
Letter of Credit No.	:	72-00-1470
Technical Office	:	FVA/PVC/CSH

MS/OP/W/CO, Room 1571, x5-1062, MGibbons, 08/22/91, FPSPC

THE SCHEDULE

ARTICLE A - PURPOSE OF GRANT

The purpose of this Grant is to provide support for FPSP's program as more fully described in its proposal dated July 15, 1991 which is incorporated by reference into this Grant, and in Attachment 2 to this Grant.

ARTICLE B - PERIOD OF PERFORMANCE

The effective date of this Grant is the date of the Cover Letter and the expiration date is September 14, 1994; funds obligated hereunder are authorized for program expenditures during the period of September 15, 1991 to September 14, 1994; the effective period

ARTICLE C - AMOUNT OF GRANT AND PAYMENT

1. A.I.D. hereby obligates the amount of \$500,000 for the purposes of this Grant. A.I.D. shall not be liable for reimbursing the Grantee for any costs in excess of the obligated amount
2. Payment shall be made to the Grantee in accordance with procedures set forth in Attachment 3 - Additional Standard Provision Number 1, entitled "Payment - Letter of Credit."
3. The total estimated cost of this project is \$675,831 as described per FPSP's letter of July 15, 1991, of which A.I D. is providing \$500,000.

ARTICLE D - FINANCIAL PLAN

- 1 FVA/PVC/CSH is contributing \$500,000 to provide support to it's program and the budget breaks down as follows:

BUDGET SUMMARY BY LINE ITEM

YEARS	One (1)		TWO (2)		THREE (3)	
	<u>AID</u>	<u>PVO</u>	<u>AID</u>	<u>PVO</u>	<u>AID</u>	<u>PVO</u>
Salaries	54,453	6,141	62,413	6,351	65,272	6,573
Fringe	24,465	2,759	28,041	2,854	29,325	2,952
Consultants	2,406	2,580	6,948	0	7,268	75,268
Travel	38,138	0	10,960	0	16,248	0
Equipment	0	22,000	0	0	0	0
Supplies	2,900	2,100	4,300	2,700	4,100	2,700
ODCs	16,220	14,450	14,920	33,850	14,920	33,850
<u>Indirect</u>	<u>33,218</u>	<u>11,992</u>	<u>30,581</u>	<u>10,967</u>	<u>32,871</u>	<u>11,044</u>
TOTAL	171,800	62,022	158,183	56,722	170,004	57,119

	TOTALS	
	<u>AID</u>	<u>PVO</u>
Salaries	182,138	19,065
Fringe	81,831	8,565
Consultants	16,622	2,580
Travel	65,346	0
Equipment	0	22,000
Supplies	11,300	7,500
ODCs	46,060	82,150
<u>Indirects</u>	<u>403,297</u>	<u>141,860</u>
TOTAL	499,967	175,864

Total Amount to be Funded by A.I.D:\$ 500,000 (rounded)
Total Amount Funded by Grantee :\$ 175,831
Total Amount of Project :\$ 675,831

2. Inclusion of any cost in the budget of this Grant does not obviate the requirement for prior approval by the Grant Officer of cost items designated as requiring prior approval by the applicable cost principles (see the Mandatory Standard Provision of this Grant set forth in Attachment 3 entitled "Allowable Costs") and other terms and conditions of this Grant.

ARTICLE E - REPORTING AND EVALUATION

1. Financial Reporting

- a. Financial reporting requirements shall be in accordance with the Additional Standard Provision of the grant entitled "Payment - Letter of Credit", as shown in Attachment 3.
- b. The original and two copies of all financial reports shall be submitted quarterly to:

A.I.D.
Office of Financial Management
FA/FM/CMPD/DC
Room 700, SA-2
Washington, D.C. 20523-0209.

In addition, two copies of all financial reports shall be submitted to the A.I.D. Project Office specified below, one copy for the Project Officer and the other copy for the official grant file in Operations Support Division.

FVA/PVC/CSH
Room 103C SA-2
A.I.D.
320 21st Street, N.W.
Washington, D.C. 20523-0008
(1) Attn: Mr. Charles Habis (or)
(2) Attn: Mr. John McEnaney
Phone: (202) 663-2616

2. Program Performance Reporting

- a. The Grantee shall submit quarterly progress reports, and a final report. These reports should document progress vis-a-vis program objectives, problems encountered, corrective procedures that were followed, significant program development during the period, and projected accomplishments for the coming quarter. Two copies of each program performance report should be submitted to FVA/PVC/CSH.

Notes: At the time all required reports are submitted by the PVO to FVA/PVC, a copy should simultaneously be sent to the A.I.D. Mission in each respective country.

Additionally, all work to be charged to this agreement, including preparation of final reports, must be completed prior to expiration of this grant.

(1) ANNUAL REPORT. Five copies of the Annual Report will be submitted to the AID/FVA/PVC Project Officer by October 15 of each year of the program; the first report is due October 15, 1992. The annual report should follow the annual report guidelines and should summarize inputs, outputs, progress to date, constraints, and highlights from the preceding year. The Report should also include reporting on the standard A I.D indicators for ORT, immunization and growth monitoring and nutrition interventions which are required of all programs receiving child survival funding. For these child survival projects, a mid-term evaluation report will replace the 2nd annual report.

The ANNUAL REPORT will also include the "USAID Health and Child Survival Project Questionnaire " This must be completed each year of the grant (including the final year) and for each PVO-funded CS project Other A.I.D.-funded grants, such as OPGs, should be identified if there is a relationship of that grant to this grant supported program

During the life-of-program, program monitoring and information on a country-specific basis will be included in the annual reporting system. Field reports prepared by the recipient's regional and technical specialists, as well as FVA/PVC consultants will also be included in the ANNUAL REPORT.

(2) INTERIM REPORTING. Prior to the required final performance reporting date, events may occur that have significant impact upon the program outcome. In such instances, the Recipient shall inform in writing the Grant Officer and the AID/FVA/PVC Project Officer as soon as the following types of conditions are known:

- (a) Problems, delays or adverse conditions that will materially affect the ability to attain program objectives, prevent the meeting of time schedules, and goals, or preclude the attainment of program work activities by the established time period. This disclosure shall be accompanied by the statement of the action taken, or contemplated, and any assistance needed to resolve the situation.
- (b) Favorable developments or events that enable time schedules to be met or work activities to be performed sooner than originally projected, resulting in an earlier than planned project completion date.

(3) MID TERM EVALUATION: A mid-term project evaluation will be scheduled in collaboration with A.I.D. The Recipient should work closely with the FVA/PVC Project Officer to plan for this evaluation including scheduling participants. The results of this evaluation will be submitted to FVA/PVC as a mid-term evaluation report in accordance with mid-term evaluation report guidelines provided by FVA/PVC.

(NOTE: with prior A.I.D. written approval an annual report may take the place of a mid-term evaluation for expansion grants.)

(4) FINAL EVALUATION. A final independent evaluation in collaboration with A.I.D. will be carried out in the final year of the program to evaluate program effectiveness and impact. This final evaluation must be completed prior to the expiration date of the agreement, in accordance with final evaluation guidelines provided by FVA/PVC. The final evaluation will be submitted to A.I.D. as part of the final report as explained below.

(5) FINAL REPORT. No later than 90 days after the expiration of the Grant period (see ARTICLE B above), a FINAL REPORT following PVC final report guidelines and including items specified by the project officer is due. The FINAL REPORT includes but is not limited to, the findings of the FINAL EVALUATION. The Final Report should follow the final evaluation guidelines, and items specified by the Project Officer. Five (5) copies will be submitted to the AID/FVA/PVC Office as specified in ARTICLE E.1 b. above. The final report will cover all information shown in ARTICLE E.2 above.

(NOTE. The A I.D Child Survival and Health Reporting Schedule must be submitted as part of the final report as well as a full financial report including a complete pipeline analysis.)

- b. The reports should briefly present the following information:
- (1) A comparison of actual accomplishments with the goals established for the period. If the output of programs or projects can be readily quantified, such quantitative data should be related to cost data for computation of unit costs.
 - (2) Reasons why established goals were not met.
 - (3) Analysis and explanation of actual costs versus budgeted costs.
 - (4) Other pertinent information including, when appropriate, analysis and explanation of cost overruns.
- c. If any performance review conducted by the Grantee discloses the need for change in the budget estimates in accordance with the criteria established in the Standard Provision of this grant entitled "Revision of Grant Budget" or by ARTICLE D.2. of this Schedule, the Grantee shall submit a request for budget revision.

ARTICLE F - SPECIAL PROVISIONS

1. For purposes of this grant, reference to "OMB Circular A-122" in the Mandatory Standard Provisions of this grant shall include the A.I.D. implementation of such Circular, as set forth in subpart 731.7 of the A.I.D. Acquisition Regulations (A.I D.A.R) (41 CFR Chapter 7).
2. The Additional Standard Provisions, appended hereto as Attachment 3, applicable to this grant are marked with an "x".
3. The geographic code for procurement of goods and services is as prescribed under Additional Standard Provision of the grant entitled "Eligibility Rules for Goods and Services Payment", as shown in Attachment 3.
4. Conflicts between any of the Attachments of this Grant shall be resolved by applying the following order of precedence:

Attachment 1 - Schedule
Attachment 2 - Program Description
Attachment 3 - Standard Provisions

5. Closeout Procedures (OMB Circular A-110)
 - a. This paragraph prescribes uniform closeout procedures for AID grants.
 - b. The following definitions shall apply for the purpose of this paragraph.

1) Closeout. The closeout of a grant is the process by which AID determines that all applicable administrative actions and all required work of the grant have been completed by the recipient and AID.

2) Date of completion. The date of completion is the date on which all work under grants is completed or the date on the award document, or any supplement or amendment thereto, on which AID sponsorship ends.

3) Disallowed costs. Disallowed costs are those charges to a grant that AID or its representative determines to be unallowable, in accordance with the applicable Federal cost principles or other conditions contained in the grant.

c. AID closeout procedures include the following requirements:

- 1) Upon request, AID shall make prompt payments to a recipient for allowable reimbursable costs under the grant being closed out.
- 2) The recipient shall immediately refund any balance of unobligated (unencumbered) cash that AID has advanced or paid and that is not authorized to be retained by the recipient for use in other grants or cooperative agreements.
- 3) AID shall obtain from the recipient within 90 calendar days after the date of completion of the grant all financial, performance, and other reports required as the condition of the grant. AID may grant extensions when requested by the recipient.
- 4) When authorized by the grant, AID shall make a settlement for any upward or downward adjustments to AID's share of costs after these reports are received.
- 5) The recipient shall account for any property acquired with AID funds, or received from the Government in accordance with any provisions of this grant.
- 6) In the event a final audit has not been performed prior to the closeout of the grant, AID shall retain the right to recover an appropriate amount after fully considering the recommendations on questioned costs resulting from the final audit.

6. Countries: The following countries are approved for direct in-country program support under this Agreement:

SOLOMAN ISLANDS

Other countries may be approved during the period of the Agreement only with the express written approval of AID/FVA/PVC.

The recipient will carry out the following activities:

- a. Submit a Detailed Implementation Plan (DIP) for each country program by April 1, 1992, in accordance with FVA/PVC guidelines. Illustrative guidelines are available from FVA/PVC and will be furnished to you in the fall of 1991.
- b. This implementation plan should include a description of how the various child survival interventions will be evaluated and should clearly define: (a) the objectives and outputs that each program will be held accountable for; (b) the specific indicators that will be used to measure program success in

reaching objectives and outputs; (c) mechanisms for collecting data, i.e. surveys, sentinel systems, etc.; and (d) manpower and other resources needed for carrying out monitoring and evaluation activities with a revised budget. The DIP should include scheduled reports, internal and external evaluations, and line item budgets.

c. Develop/adopt a program-specific Health Information System, responsive to needs of field programs and headquarters and be able to provide A.I.D. with information for tracking program performance. This system should be described in the first year progress report.

ARTICLE G - INDIRECT COST RATES

1. Pursuant to the Additional Standard Provision of this grant entitled "Negotiated Indirect Cost Rates - Provisional", the allowable indirect costs under this Grant Number PDC-0500-G-00-1075-00 shall be obtained by applying the provisional indirect cost rate to the base agreed upon by the Grantee and A.I.D. The following indirect rate agreed to by the Grantee shall be the billing rate used during the full period of performance of this Grant, as set forth in ARTICLE B above.

INDIRECT COST RATES

<u>TYPE</u>	<u>RATE</u>	<u>APPLICABLE TO</u>
Provisional	23.9	Modified total cost excluding salaries in kind, grants and awards and equipment (A.I.D. only)

ATTACHMENT TWO (2)

GRANT NO. PDC-0500-G-00-1075-00

PROGRAM DESCRIPTION

FOR

SOLOMAN ISLANDS (PAGE 1)

A. SUMMARY DESCRIPTION OF PROJECT

The proposed project will be implemented in Solomon Islands, a Melanesian nation just south of Papua New Guinea, consisting of six large islands and hundreds of small islands, and 331,505 people spread out over 500,000 kilometers of the Pacific Ocean.

The Ministry of Health and Medical Services in Solomon Islands has recently instituted a Maternal and Child Health Unit to house its immunization, diarrheal disease, family planning and nutrition activities. A national EPI program has been firmly established over the past two years, and although coverage rates are still low, significant improvements continue to be made with the assistance of the Australian Save the Children Fund. The MCH Unit considers its next priority to be a national Control of Diarrheal Disease (CDD) Program to begin to combat the country's second leading reported cause of morbidity and mortality of children under five. The Ministry has requested assistance from The Foundation for the Peoples of the South Pacific (FSP) with the design, implementation, monitoring and evaluation of a National CDD Program. With the recent identification of a CDD Coordinator, the MCH Unit is poised to commence the process of quantifying the problem, assessing the resources and designing an appropriate program.

The target population of 65,305 includes all children under five. The goal of the project is to reduce morbidity and mortality associated with diarrheal disease in these children through improving the treatment of diarrhea and dehydration cases brought to a health facility; improving mothers' knowledge and practice relating to treatment of diarrhea in the home, and improving mothers' knowledge of how to prevent diarrhea through breastfeeding, proper weaning practices, measles immunization and improved hygiene.

Towards these objectives, the project will 1) assist the MHMS to design a national program and determine national policy, 2) develop materials for training and health education, 3) educate in-service and pre-service health professionals in case management, 4) train auxiliary health workers to educate mothers in prevention and treatment of diarrhea in children, and 5) use community groups as channels for dissemination of health education.

\$440,000 is requested from USAID with a \$150,000 match by FSP for a total of \$590,000 to be expended over thirty-six months. The average total annual budget will be \$196,000

FSP has twenty years experience working in development in Solomon Islands, and has the field and headquarters technical and administrative expertise, and track record, required to implement a sustainable program. The project will strengthen the capacity of the Solomon Islands Ministry of Health and FSP's local NGO partner, Soltrust, to implement Child Survival interventions

SPECIAL PROVISION 40.1ALKALOIDS, ANTIBIOTICS, VIATAMINS AND RELATED PRODUCTS

(SEE SPECIFIC SCHEDULE B NUMBERS COVERED BY THIS SPECIAL PROVISION UNDER PART II.D. OF THE LISTING.)

I. Special Requirements**A. Expiration Dates**

Not more than 1/6 of full dating periods from 1 to 18 months, nor 1/3 of full dating periods of more than 18 months shall have expired on the date of shipment.

B. Identification

Each unit package shall bear labels which identify the contents by generic name. In the case of products consisting of more than one active ingredient, generic name and quantity of each active ingredient must be provided. Shall be additionally identified "USP" OR "NF," if covered by specifications of the U.S. Pharmacopeia or the National Formulary of the United States.

C. Professional Samples

Professional samples shall not be furnished in connection with AID-financed sales of drug substances and/or products in other than finished dosage form. If sales of finished-dosage forms are eligible for AID financing, any professional samples furnished in connection with such sales shall be at the supplier's expense and must contain less than the manufacturer's smallest available commercial package (but not less than an individual dose) of the same product. Each professional sample shall clearly state in its label "Professional Sample."

D. Invoices

Invoices must itemize each drug substance and/or product for which payment is claimed. The following information regarding each line item must be provided either on the face of the invoice or on an attachment thereto.

1. General Information

a. The quantity of each active ingredient in each item billed. Each active ingredient shall be identified by its "established

(TM 15:93)
Jan. 27, 1989

name" and additionally identified as "USP" OR "NF," if specifications covering such material are included under established names in the U.S. Pharmacopeia or the National Formulary of the United States. "Established Name" is defined in Section 502(e) (2) of the Federal Food, Drug and Cosmetic Act.

b. The actual expiration date for each item billed, or an indication that no expiration date applies.

c. An itemized accounting of any professional samples related to AID-financed transactions, whether or not shipped separately.

2. Additional information, if invoices include:

a. Insulin

(1) List applicable batch numbers.

(2) Attach copies of pertinent Federal Food and Drug Certificates.

b. Drug substances and/or products shipped from a free port or bonded warehouse

(1) Specify operation(s) performed on the item if it or its packaging was changed in any manner while in the free port or bonded warehouse.

(2) List the name and address of the manufacturer who produced the ingredient(s) used in invoiced items.

II. Additional Documentation Required for Reimbursement

A certificate, by or for the supplier, endorsed on or attached to the invoice, as follows:

"The undersigned supplier, or agent acting in behalf of and authorized to bind the supplier, agrees with and certifies to AID that he has complied in full with each of the special requirements for AID financing of drug substances and/or products (AID Special Provision 40.1); guarantees that, on date of shipment, no item for which payment is now claimed is adulterated or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act, and is not an article which may not, under provisions of Sections 404 or 505 of that Act, be introduced into interstate commerce; and will, with respect to violation of any such requirement or guarantee make, upon demand, full and complete refund to AID of any sum received by the supplier as AID financing for any product which is the subject of such a violation."

(TM 15:93)
Jan. 27, 1989

II.D.5: ELIGIBILITY LISTING - PHARMACEUTICALS

		Eligible	Ineligible	Special Provisions
1507.90.2000	SOYBEAN OIL, PHARMACEUTICAL GRADE	X		40.1
2907.29.3000	POLYPHENOL DRUGS, N.E.S.O.I.	X		40.1
2908.10.2000 - 2908.10.6000	DERIVATIVES CONTAINING ONLY HALOGEN SUBSTITUENTS AND THEIR SALTS	X		40.1
2922.19.1800	AROMATIC DRUGS OF AMINO-ALCOHOLS	X		40.1
2922.49.2000	AROMATIC DRUGS OF AMINO-ACIDS	X		40.1
2924.29.0020	AROMATIC DRUGS OF ACYCLIC AMIDES	X		40.1
2925.20.1500	AROMATIC DRUGS OF IMINES AND THEIR DERIVATIVES	X		40.1
2928.00.3000	AROMATIC DRUGS OF METHYL ETHYL KETOXIME	X		40.1
2930.90.4530 - 2930.90.5060	OTHER ORGANO-SULFUR COMPOUNDS	X		40.1
2931.00.2200	AROMATIC DRUGS OF OTHER ORGANO-INORGANIC COMPOUNDS	X		40.1
2931.00.6000	OTHER ORGANO-INORGANIC COMPOUNDS	X		40.1
2932.29.2000	AROMATIC DRUGS OF LACTONES	X		40.1
2933.40.2200	DRUGS OF COMPOUNDS CONTAINING A QUINOLINE OR ISOQUINOLINE RING SYSTEM	X		40.1
2933.59.2100	DRUGS OF HETEROCYCLIC COMPOUNDS WITH NITROGEN HETERO-ATOM(S) CONTAINING A PYRIMIDINE RING	X		40.1
2933.90.2600 - 2933.90.3600	AROMATIC DRUGS OF HETEROCYCLIC COMPOUNDS WITH NITROGEN HETRO-ATOM(S)	X		40.1
2934.30.2000 - 2934.30.3000	DRUGS OF HETEROCYCLIC COMPOUNDS CONTAINING A PHENOTHIAZINE RING-SYSTEM	X		40.1
2935.00.4000	SULFONAMIDE DRUGS	X		40.1
2936.10.0000 - 2936.90.0000	PROVITAMINS, VITAMINS AND THEIR DERIVATIVES	X		40.1

(TM 15:93)
Jan. 27, 1989

		Eligible	Ineligible	Special Provisions
2937.10.0000 - 2937.99.0000	HORMONES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES THEREOF, USED PRIMARILY AS HORMONES; OTHER STEROIDS USED PRIMARILY AS HORMONES	X		40.1
2938.10.0000 - 2939.90.0000	GLYCOSIDES AND VEGETABLE ALKALOIDS, NATURAL OR REPRODUCED BY SYNTHESIS, AND THEIR SALTS, ETHERS, ESTERS AND OTHER DERIVATIVES	X		40.1
2941.10.1000 - 2941.10.6000	PENICILLINS AND THEIR DERIVATIVES WITH A PENICILLANIC ACID STRUCTURE; SALTS THEREOF	X		40.1
2941.20.0000	STREPTOMYCINS AND THEIR DERIVATIVES; SALTS THEREOF	X		40.1
2941.30.0000	TETRACYCLINES AND THEIR DERIVATIVES; SALTS THEREOF	X		40.1
2941.40.0000	CHLORAMPHENICOL AND ITS DERIVATIVES; SALTS THEREOF	X		40.1
2941.50.0000	ERYTHROMYCIN AND ITS DERIVATIVES, SALTS THEREOF	X		40.1
2941.90.1000 - 2941.90.6000	OTHER ANTIBIOTICS	X		40.1
3001.10.0000 - 3001.90.0000	GLANDS AND OTHER ORGANS FOR ORGANO-THERAPEUTIC USES		X	
3002.10.0010 - 3002.10.0050	ANTISERA AND OTHER BLOOD FRACTIONS		X	
3002.20.0000	VACCINES FOR HUMAN MEDICINE	<u>1/</u>		40.2
3002.31.0000 - 3002.39.0000	VACCINES FOR VETERINARY MEDICINE	<u>1/</u>		40.3
3002.90.1000	FERMENTS		X	
3002.90.5010	WHOLE HUMAN BLOOD		X	
3002.90.5020	ANTIALLERGENIC PREPARATIONS	<u>1/</u>		40.2

1/LOCAL AUTHORITIES ARE TO DETERMINE THAT APPROVED IMPORTERS HAVE ADEQUATE STORAGE AND DISTRIBUTION FACILITIES TO ASSURE PROPER PROTECTION FOR THE QUANTITIES AUTHORIZED TO BE IMPORTED.

(TM 15:93)
Jan. 27, 1989

		Eligible	Ineligible	Special Provisions
3002.90.5050	OTHER TOXINS, CULTURES OF MICRO-ORGANISMS AND SIMILAR PRODUCTS		X	
3003.10.0000	MEDICAMENTS CONTAINING PENICILLINS OR DERIVATIVES THEREOF, WITH A PENICILLANIC ACID STRUCTURE, OR STREPTOMYCINS OR THEIR DERIVATIVES, NOT PACKAGED FOR RETAIL SALE	X		40.1
3003.20.0000	MEDICAMENTS CONTAINING OTHER ANTIBIOTICS, NOT PACKAGED FOR RETAIL SALE	X		40.1
3003.31.0000 - 3003.39.0000	MEDICAMENTS CONTAINING HORMONES OR OTHER PRODUCTS OF HEADING 2937 BUT NOT CONTAINING ANTIBIOTICS, NOT PACKAGED FOR RETAIL SALE	X		40.1
3003.40.0000	MEDICAMENTS CONTAINING ALKALOIDS OR DERIVATIVES THEREOF BUT NOT CONTAINING HORMONES OR OTHER PRODUCTS OF HEADING 2937, OR ANTIBIOTICS, NOT PACKAGED FOR RETAIL SALE	X		40.1
3003.90.0000	OTHER MEDICAMENTS CONSISTING OF TWO OR MORE CONSTITUENTS WHICH HAVE BEEN MIXED TOGETHER FOR THERAPEUTIC OR PROPHYLACTIC USES, NOT PACKAGED FOR RETAIL SALE	X		40.1
3004.10.1010	MEDICAMENTS CONTAINING PENICILLINS OR DERIVATIVES THEREOF, WITH A PENICILLANIC ACID STRUCTURE, OR STREPTOMYCINS OR THEIR DERIVATIVES, CONTAINING PENICILLIN G SALTS; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.10.1020 - 3004.10.1045	MEDICAMENTS CONTAINING PENICILLINS OR DERIVATIVES THEREOF, WITH A PENICILLANIC ACID STRUCTURE, OR STREPTOMYCINS OR THEIR DERIVATIVES, CONTAINING PENICILLIN G SALTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.10.5010	MEDICAMENTS CONTAINING PENICILLINS OR DERIVATIVES THEREOF, WITH A PENICILLANIC ACID STRUCTURE, OR STREPTOMYCINS OR THEIR DERIVATIVES; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3

(TM 15:93)
Jan. 27, 1989

		Eligible	Ineligible	Special Provisions
3004.10.5045 - 3004.10.5060	MEDICAMENTS CONTAINING PENICILLINS OR DERIVATIVES THEREOF, WITH A PENICILLANIC ACID STRUCTURE, OR STREPTOMYCINS OR THEIR DERIVATIVES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.20.0010	MEDICAMENTS CONTAINING OTHER ANTIBIOTICS; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.20.0020 - 3004.20.0050	MEDICAMENTS CONTAINING OTHER ANTIBIOTICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.31.0000 - 3004.32.0000	MEDICAMENTS CONTAINING HORMONES OR OTHER PRODUCTS OF HEADING 2937 BUT NOT CONTAINING ANTIBIOTICS; PUT UP IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.39.0010	MEDICAMENTS CONTAINING HORMONES OR OTHER PRODUCTS OF HEADING 2937, BUT NOT CONTAINING ANTIBIOTICS; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.39.0050	OTHER MEDICAMENTS CONTAINING HORMONES OR OTHER PRODUCTS OF HEADING 2937, BUT NOT CONTAINING ANTIBIOTICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0005	MEDICAMENTS CONTAINING ALKALOIDS OR DERIVATIVES THEREOF BUT NOT CONTAINING HORMONES, OTHER PRODUCTS OF HEADING 2937, OR ANTIBIOTICS; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.40.0010	CARDIOVASCULAR MEDICAMENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0020	ANTICONVULSANTS, HYPNOTICS, AND SEDATIVES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1

		Eligible	Ineligible	Special Provisions
3004.40.0030	ANTIDEPRESSANTS, TRANQUILIZERS, AND OTHER PSYCHOTHERAPEUTIC AGENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0040	OTHER MEDICAMENTS PRIMARILY AFFECTING THE CENTRAL NERVOUS SYSTEM; PUT UP IN DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0050	DERMATOLOGICAL AGENTS AND LOCAL ANESTHETICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0060	MEDICAMENTS PRIMARILY AFFECTING THE EYES, EARS OR RESPIRATORY SYSTEM; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.40.0070	OTHER MEDICAMENTS CONTAINING ALKALOIDS OR DERIVATIVES THEREOF, BUT NOT CONTAINING HORMONES, OTHER PRODUCTS OF HEADING 2937, OR ANTIBIOTICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.50.4500	VITAMINS, SYNTHESIZED WHOLLY OR IN PART FROM AROMATIC INDUSTRIAL ORGANIC COMPOUNDS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.50.5005	VITAMINS FOR VETERINARY USE; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.50.5010	SINGLE VITAMINS COMBINED WITH MINERALS OR OTHER NUTRIENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.50.5020	OTHER SINGLE VITAMINS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1

		Eligible	Ineligible	Special Provisions
3004.50.5030	MULTIPLE VITAMINS COMBINED WITH MINERALS OR OTHER NUTRIENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.50.5040	OTHER MULTIPLE VITAMINS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.1000	MEDICAMENTS CONTAINING ANTIGENS OR HYALURONIC ACID OR ITS SODIUM SALT; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5003	MEDICAMENTS CONTAINING ANTIGENS OR HYALURONIC ACID OR ITS SODIUM SALT; FOR VETERINARY USE, PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.3
3004.90.5005	SULFONAMIDES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5010	OTHER ANTI-INFECTIVE MEDICAMENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5015	ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE MEDICAMENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5020	CARDIOVASCULAR MEDICAMENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5025	ANALGESICS, ANTIPYRETICS, AND NON-HORMONAL ANTI-INFLAMMATORY AGENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5030	ANTICONVULSANTS, HYPNOTICS, AND SEDATIVES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1

		Eligible	Ineligible	Special Provisions
3004.90.5035	ANTIDEPRESSANTS, TRANQUILIZERS, AND OTHER PSYCHOTHERAPEUTIC AGENTS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5040	OTHER MEDICAMENTS PRIMARILY AFFECTING THE CENTRAL NERVOUS SYSTEM; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.5045	DERMATOLOGICAL AGENTS AND LOCAL ANESTHETICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6050	LAXATIVES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6055	ANTACIDS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6060	OTHER MEDICAMENTS PRIMARILY AFFECTING THE DIGESTIVE SYSTEM; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6065	DIURETICS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6070	OTHER MEDICAMENTS PRIMARILY AFFECTING ELECTROLYTIC, CALORIC, OR WATER BALANCE; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6075	COUGH AND COLD PREPARATIONS; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6080	ANTIHISTAMINES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3004.90.6085	OTHER MEDICAMENTS PRIMARILY AFFECTING THE EYES, EARS OR RESPIRATORY SYSTEM; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1

(TM 15:93)
Jan. 27, 1989

		Eligible	Ineligible	Special Provisions
3004.90.6090	OTHER MEDICAMENTS CONSISTING OF MIXED OR UNMIXED PRODUCTS FOR THERAPEUTIC OR PROPHYLACTIC USES; PUT UP IN MEASURED DOSES OR IN FORMS OR PACKINGS FOR RETAIL SALE	X		40.1
3005.10.0000 - 3005.90.0000	WADDING, GAUZE, BANDAGES AND SIMILAR ARTICLES IMPREGNATED OR COATED WITH PHARMECEUTICAL SUBSTANCES, FOR MEDICAL, SURGICAL, DENTAL OR VETERINARY PURPOSES	X		
3006.10.0000	STERILE SURGICAL CATGUT, SIMILAR STERILE SUTURE MATERIALS AND STERILE TISSUE ADHESIVES; STERILE LAMINARA TENTS; STERILE ABSORBABLE SURGICAL OR DENTAL HAEMOSTATICS	X		
3006.20.0000	BLOOD-GROUPING REAGENTS	X		
3006.30.0000	OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS DESIGNED TO BE ADMINISTERED TO THE PATIENT	X		
3006.40.0000	DENTAL CEMENTS AND OTHER DENTAL FILLINGS; BONE REPLACEMENT CEMENT	X		
3006.50.0000	FIRST-AID BOXES AND KITS	X		
3006.60.0000	CHEMICAL CONTRACEPTIVE PREPARATIONS BASED ON HORMONES OR SPERMICIDES	<u>1/</u>		
3507.10.0000 - 3507.90.0000	ENZYMES	X		40.1
9602.00.1040	UNFILLED GELATIN CAPSULES	X		40.1

1/ WHEN PROCUREMENT OF ANY COMMODITY UNDER THIS CATEGORY IS PROPOSED, AID/W WILL FURNISH THE USAID WITH THE SPECIAL PROVISION WHICH IS APPLICABLE.

(TM 15:93)
Jan. 27, 1989

AID 1350 1 3871 *PIO T AGENCY FOR INTERNATIONAL DEVELOPMENT PROJECT IMPLEMENTATION ORDER/TECHNICAL SERVICES	1 Cooperating Country Centrally Funded	Page 1 of _____ Pages
	2 PIO/T No 1385018	3 <input checked="" type="checkbox"/> Original or Amendment No _____
	4 Project Activity No and Title 938-0500 The Foundation for the Peoples of the South Pacific (FSP)	

DISTRIBUTION Initials: _____ Date Posted: _____ PPM/FM/AV/PNP FONDS RESERVED BY: _____ 5/22/91	5 Appropriation Symbol 72-1111021.7	6 Budget Plan Code 147-38-099-00-76-11 EDCA-91 13810 KG11
	7 Obligation Status <input checked="" type="checkbox"/> Administrative Reservation <input type="checkbox"/> Implementing Document	8 Project Assistance Completion Date (Mo Day Yr)
	9 Authorized Agent A.I.D./W	10 This PIO T is in full conformance with PRO/AG No _____ Date _____
	11a Type of Action and Governing AID Handbook <input type="checkbox"/> AID Contract (HB 14) <input checked="" type="checkbox"/> AID Grant or Cooperative Agreement (HB 13) <input type="checkbox"/> PASA RSSA (HB 12) <input type="checkbox"/> Other	11b Contract/Grant/Cooperative Agreement/PASA/RSSA Reference Number (if this is an Amendment)

12 Estimated Financing (A detailed budget in support of column (2) is attached as Attachment No _____)					
Maximum AID Financing Available	A Dollars	(1) Previous Total	(2) Increase	(3) Decrease	(4) Total to Date
			500,000		500,000
	B U.S. Owned Local Currency				

14A Instructions to Authorized Agent
 SER/OP/W/MS is requested to execute a three-year child survival agreement with the Foundation for the Peoples of the South Pacific (FSP) for a total LOP of \$500,000 effective September 1, 1991 to August 31, 1994. The Solomon Islands program should be fully funded this year.

 Please clear this agreement with Project Officer before sending to PVO.

14B Address of Voucher Paying Office
**PPM/FM/CMPD, Room 700, SA-2
 Washington, D.C. 20523**

15 Clearances—Include typed name, office symbol, telephone number and date for all clearances			
A The Project Officer certifies that the specifications in the statement of work or program description are technically adequate	Phone No 32616	B The statement of work or program description lies within the purview of the issuing office and approved agency programs	Date 5/16/91
	Date 5-15-91		
FVA/PVC/CSH: CHabis <i>cmh</i>		FVA/PVC/IPS:LWatlington <i>lw</i>	
C FVA/PVC/CSH: JMcEnane <i>JME</i>	Date 5/16/91	D Funds for the services requested are available	Date
E FVA/PPM/PMS: EJefferson <i>ej</i>	Date 5-17-91		

16 For the Cooperating Country: The terms and conditions set forth herein are hereby agreed to	17 For the Agency for International Development
Signature _____ Date _____	Signature <i>Carlos Quiros</i> Date 5-17-91
Title _____	Title Carlos Quiros, Director, FVA/PPM

*See HB 3 Sup A App C Att B for preparation instructions. Note: The completed form contains sensitive information whose unauthorized disclosure may subject an employee to disciplinary action.

OFFICE OF FINANCIAL MANAGEMENT
 PPM/FM/AV/PNP
 5/22/91
 FONDS RESERVED BY: